← All indications
Inflammatory Bowel Diseases
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
Subtype terms (2)
More specific conditions that are subtypes of Inflammatory Bowel Diseases in the MeSH hierarchy.
- Colitis, Ulcerative
411 drugs (148 approved, 263 experimental)
- Crohn Disease
340 drugs (156 approved, 184 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (45)
- ferric derisomaltose
- propofol
- aminosalicylic acid
- mercaptopurine
- lubiprostone
- captafer
- golimumab
- ibuprofen
- betamethasone
- epaxal
- ferric carboxymaltose
- ferric maltol
- ferric sulfate
- fidaxomicin
- folic acid
- fumaric acid esters
- iron dextran
- iron sucrose
- liposomal iron
- adalimumab
- prucalopride succinate
- epinephrine
- risankizumab
- sitagliptin
- celecoxib
- bupivacaine
- thiopurine
- ustekinumab
- vancomycin
- vedolizumab
- +15 more
Phase 3 trials (37)
- thalidomide
- vitamin d3
- kremezin
- balsalazide
- prednisone
- cannabidiol
- ferrous fumarate
- iron hydroxide dextran
- Diatrizoate
- mesalamine
- imiquimod
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- mirikizumab
- vitamin c
- sodium picosulfate
- hepatitis b vaccine (recombinant)
- sucrosomial iron
- fluconazole
- tripterygium wilfordii
- valganciclovir
- agaricus blazei murill
- bifidobacterium infantis
- bifidobacterium breve
- bifidobacterium longum
- human fecal microbiota
- inactivated influenza vaccine
- lactobacillus plantarum
- vsl #3
- streptococcus salivarius
- fenofibrate
- +7 more
Phase 2 trials (47)
- metformin
- metronidazole
- 23-valent pneumococcal polysaccharide vaccine
- secukinumab
- apd-334
- urea
- bay94-9392
- beta-hydroxybutyrate
- daclizumab
- filgotinib
- naltrexone
- khk4083
- nolpitantium besylate
- oprelvekin
- terbinafine
- atorvastatin
- pneumococcal 13-valent conjugate vaccine
- lidocaine
- qbeco
- ranolazine
- ceftriaxone
- Vidofludimus
- sirolimus
- cannabis
- mesalazine
- pentoxifylline
- itraconazole
- fructo-oligosaccharide
- mastiha
- wharton's jelly mesenchymal stem cells
- +17 more
Phase 1 trials (51)
- allopurinol
- methylprednisolone
- akb-4924
- alicaforsen
- bone autograft
- kcc heptapeptide
- Milategrast
- empagliflozin
- ethinyl estradiol
- gsk-1070806
- gsk1399686
- gsk2982772
- hemay007
- rosuvastatin
- nivolumab
- cholera vaccine
- pf-06480605
- pf-06687234
- allogeneic hematopoietic stem cells
- Izencitinib
- pacritinib
- xylitol
- allogeneic adipose derived mesenchymal stem cell
- autologous bone marrow derived mesenchymal cells
- curcumin
- microbiota
- ganglioside
- bovine immunoglobin
- sucralose
- apixaban
- +21 more
Other trials (40)
- maltodextrin
- bacillus clausii
- briakinumab
- carbon dioxide
- cefazolin
- certolizumab pegol
- nabilone
- etanercept
- calcium
- lactulose
- magnesium oxide
- whey protein
- mupirocin
- oligofructose-enriched inulin
- cow milk
- pectin
- peripheral blood lymphocytes
- ribavirin
- levobupivacaine
- senna alexandrina
- sodium butyrate
- nicotinamide
- pantothenic acid
- ficus carica
- fructan
- resistant starch
- silymarin
- pyridoxine
- indigotindisulfonate sodium
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- +10 more
Organizations
Organization Involved with Phase 4 Indications (56)
- AbbVie
- Daiichi Sankyo
- Takeda
- Astellas
- Merck
- Pfizer
- Pharmacosmos
- Sucampo
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Pennsylvania
- Maastricht University
- University of Pittsburgh
- Algemeen Ziekenhuis Maria Middelares
- Boston University
- Cedars-Sinai Medical Center
- University of London
- Teaching Hospital Královské Vinohrady (FNKV)
- Federal University of Juiz de Fora
- Katholieke Universiteit Leuven
- Onze Lieve Vrouw Hospital
- Sheffield Hallam University
- The Baruch Padeh Medical Center, Poriya
- Universidad Autonoma de Madrid
- University of Groningen
- University of South Alabama
- University of Tennessee
- University of Alberta
- Yale University
- Mayo Clinic
- University of British Columbia
- +26 more
Organization Involved with Phase 3 Indications (41)
- Bausch Health Companies
- Cellerix
- Institut Pasteur
- Ocera Therapeutics
- Parexel
- Shield Therapeutics
- Vifor Inc.
- Institut National de la Santé Et de la Recherche Médicale, France
- Nanjing Medical University
- Nanjing University
- New York University
- Osaka University
- Pierre and Marie Curie University
- University of Florence
- University of Messina
- University of Oslo
- University of Pavia
- University of Pisa
- University of Adelaide
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (GETAID)
- University of Vienna
- University of Trieste
- The University of Hong Kong
- Friedrich Schiller University
- University of Genoa
- University of Paris
- University of Brescia
- University of Illinois at Chicago
- Canadian Institutes of Health Research (CIHR)
- German Federal Ministry of Education and Research
- +11 more
Organization Involved with Phase 2 Indications (47)
- 4SC AG
- Facet Biotech
- Bristol-Myers Squibb
- Galapagos NV
- Gilead Sciences
- Sanofi
- Wyeth
- Novartis
- Arena Pharmaceuticals
- GlaxoSmithKline
- Kyowa Hakko Kirin
- National Center for Complementary and Integrative Health (NCCIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Third Military Medical University
- Brown University
- Cornell University
- Harvard University
- Emory University
- Harokopio University
- Indiana University
- McGill University
- Postgraduate Institute of Medical Education and Research
- Santa Barbara Cottage Hospital
- University of Jordan
- University of Maryland
- University of Melbourne
- University of Michigan
- Wayne State University
- Stony Brook University
- Tel Aviv University
- +17 more
Organization Involved with Phase 1 Indications (29)
- Eisai
- Zealand Pharma
- Theravance
- Millennium Pharmaceuticals
- Hemay Pharmaceutical PTY. LTD.
- Olympus Biotech Corporation
- National Cancer Institute (NCI)
- Seattle Children's Hospital
- University of Washington
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- McMaster University
- Michigan State University
- Thomas Jefferson University
- University of Zurich
- Xiamen University
- University of California, San Francisco
- University of Cambridge
- University of Colorado, Denver
- Hutchison MediPharma
- The Spectrum Health Group
- Mitsubishi Tanabe
- University of Montreal
- University of Texas at Houston
- Pennsylvania State University
- University of Western Ontario
- Children's National Medical Center
- University of Colorado
- South-Eastern Norway Regional Health Authority
- Chinese Academy of Medical Sciences
Organization Involved with Other Experimental Indications (38)
- Centocor
- Beneo GmbH
- VSL Pharmaceuticals
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Center for Research Resources (NCRR)
- University of Roma La Sapienza
- Aarhus University
- Case Western Reserve University
- Hillel Yaffe Medical Center
- Lund University
- Malmö University
- Medical University of Gdansk
- Medical University of Warsaw
- Radboud University
- Silesian University of Medicine
- Texas A&M University
- University of Ottawa
- Utrecht University
- University of Bologna
- Wroclaw Medical University
- Poznan University
- University of Calgary
- University of Chicago
- Zhejiang University
- Leiden University
- Klinikum Westbrandenburg
- University of Lille
- Sun Yat-Sen University
- Technion University
- Hyogo Medical University
- +8 more